US FDA Oncology Leadership Shuffle Moves Patricia Keegan To OCE; Gootenberg Takes On Recruitment
Executive Summary
US FDA's reorganization of drug reviews splits Keegan's old OHOP division into two.
You may also be interested in...
Drug Review Reorganization At US FDA Coming Into Focus
Oncology, neuroscience, and infectious diseases get acting directors as the expansion and renovation of the Office of New Drugs moves into Phase II.
Oncology Pilot To Highlight Disagreements Between US FDA And Sponsor For Advisory Committees
'Point/Counterpoint' program grew out of Assessment Aid initiative in the Oncology Center of Excellence and will be unveiled at an upcoming ODAC meeting.
OND Reorg Getting Warm Welcome From Review Divisions
Division directors are embracing the reorganization of US FDA's drug review operations.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: